EX-16.1 2 f8k042219ex16-1_optimizerx.htm LETTER FROM SADLER, GIBB & ASSOCIATES, LLC TO THE SECURITIES AND EXCHANGE COMMISSION

Exhibit 16.1

 

 

 

April 25, 2019

 

U.S. Securities and Exchange Commission

Office of the Chief Accountant

100 F Street, N.W.

Washington, D.C. 20549-7561

 

Re: OptimizeRx Corporation

 

Dear Sir or Madam:

 

We have read the statements of OptimizeRx Corporation relating to the events described under Item 4.01 of Form 8-K dated April 22, 2019 and we agree with such statements as they pertain to our Firm.

 

Sincerely,

 

/s/ Sadler, Gibb & Associates, LLC

 

Sadler, Gibb & Associates, LLC